Press release No. 19/2024 23/10/2024

AIFA Board of Directors approves 6 medicines

The AIFA Board of Directors, in its September and October meetings, approved 6 medicines, including new molecules, generic medicines, extensions of therapeutic indications and new packages of medicines already authorised.
Among these, a new medicine to be used as an add-on therapy to the standard treatment for generalised myasthenia gravis, a generic medicine indicated for the treatment of adults with chronic myeloid leukaemia, an extension of the therapeutic indications of a medicine for the treatment of HIV type 1.

The following medicines have been authorised and admitted to reimbursement by the NHS:

New medicine:

- **Zilbrysq (zilucoplan)**, an add-on therapy to standard therapy for the treatment of generalised myasthenia gravis (gMG) in adult patients positive for anti-acetylcholine receptor (AChR) antibodies.

Extension of therapeutic indications:

- **Biktarvy (Bictegravir/emtricitabine/tenofovir alafenamide fumarate)**, treatment of human immunodeficiency virus type 1 (HIV 1) infection. The indication has been extended to the paediatric population aged 2 years and older and with a body weight of at least 14 kg.

Generic medicine:

- **Nilotinib Accord (nilotinib)**, treatment of adult patients with Philadelphia chromosome-positive chronic myeloid leukaemia (CML).

New packages of the medicines Deferasirox Glenmark (deferasirox), for the treatment of chronic iron overload, Opzelura (Ruxolitinib), for vitiligo, Proplex (Factors IX, II, VII and X in combination), for the treatment and prophylaxis of bleeding, have also been authorised.

N.B. The therapeutic indications of the medicines mentioned are reported in full in the attachments to this press release.